News

The initiative aligns with China’s and the United Arab Emirates’ (UAE) broader strategic objectives to enhance healthcare and the life sciences industry. The MoU was signed by Arcera

The post Arcera and Fosun sign MoU for neuroscience innovation appeared first on Pharmaceutical Business review.

The PRV was awarded after the US Food and Drug Administration (FDA) granted accelerated approval for the Kresladi (marnetegragene autotemcel) gene therapy. Kresladi comprises the patient’s own haematopoietic stem cells that

The post Rocket to sell PRV for $180m to advance gene therapy pipeline appeared first on Pharmaceutical Business review.

The deal was originally announced in December 2025. With the acquisition, BioMarin adds two new treatments for lysosomal storage diseases, Galafold (migalastat) for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) +

The post BioMarin acquires Amicus Therapeutics for $4.8bn appeared first on Pharmaceutical Business review.

The approval allows adults with SLE on standard therapy to inject Saphnelo themselves. It is supported by results from the Phase III TULIP-SC trial, which demonstrated that subcutaneous

The post FDA approves AstraZeneca’s Saphnelo for SLE appeared first on Pharmaceutical Business review.

The European Commission (EC) has approved Novartis’ Rhapsido (remibrutinib) for certain CSU patients, becoming the first oral treatment for the skin disease. Rhapsido is approved for adult CSU

The post Novartis secures pair of regulatory wins for skin disease and malaria treatments appeared first on Pharmaceutical Business review.

Organon, created through a spinoff from Merck & Co (MSD) in 2021, distributes more than 70 products across women’s health and general medicines, including biosimilars, reaching 140 countries.

The post Sun Pharma to acquire Organon for $11.75bn appeared first on Pharmaceutical Business review.

The initiative aims to link external scientific data with internal R&D planning by creating a unified system that supports decision-making, improves market forecasting, and helps prioritise strategic investments.

The post OZMOSI and Planview partner to enhance pharmaceutical data integration appeared first on Pharmaceutical Business review.

Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. The partnership aims to establish a robust platform for speciality medicines

The post Cumberland to sell drug portfolio to Apotex for $100m appeared first on Pharmaceutical Business review.

The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from

The post Sanofi receives FDA approval for Tzield in paediatric diabetes appeared first on Pharmaceutical Business review.

The collaboration aims to implement an agentic platform across MSD’s research and development (R&D), commercial, manufacturing and corporate divisions, with Google Cloud engineers working directly with MSD teams

The post MSD teams up with Google Cloud on agentic AI transformation appeared first on Pharmaceutical Business review.